A detailed history of Bronte Capital Management Pty Ltd. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bronte Capital Management Pty Ltd. holds 19,856 shares of VRTX stock, worth $9.8 Million. This represents 0.82% of its overall portfolio holdings.

Number of Shares
19,856
Previous 19,819 0.19%
Holding current value
$9.8 Million
Previous $9.29 Million 0.59%
% of portfolio
0.82%
Previous 0.79%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$460.0 - $505.78 $17,020 - $18,713
37 Added 0.19%
19,856 $9.23 Million
Q2 2024

Aug 07, 2024

SELL
$392.81 - $485.53 $313,462 - $387,452
-798 Reduced 3.87%
19,819 $9.29 Million
Q1 2024

May 13, 2024

SELL
$407.69 - $446.08 $58,299 - $63,789
-143 Reduced 0.69%
20,617 $8.62 Million
Q4 2023

Feb 07, 2024

BUY
$343.0 - $410.68 $7.12 Million - $8.53 Million
20,760 New
20,760 $8.45 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $127B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Bronte Capital Management Pty Ltd. Portfolio

Follow Bronte Capital Management Pty Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bronte Capital Management Pty Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Bronte Capital Management Pty Ltd. with notifications on news.